MedTrace Logo

Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

NCT03692442 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2018-10-02

No results posted yet for this study

Summary

In order to understand the efficacy and side effects of lung cancer immunotherapy, at least 30 patients with lung cancer who were treated with immunotherapy were enrolled. The second-generation sequencing technology and liquid phase factor platform were used for detection, and clinical imaging and other evaluation methods were used to explore the immunotherapy efficacy and side effects affecting lung cancer。

Conditions

  • Lung Cancer Non-small Cell Stage IV

Sponsors & Collaborators

  • GeneCast Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • Guangzhou Institute of Respiratory Disease

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-01-31
Completion
2019-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692442 on ClinicalTrials.gov